• Rights offering successfully completed and private placement oversubscribed
• Acquisition of Expedeon Holdings Ltd. secured
• Gross proceeds to cover additional cash payments to Expedeon shareholders and transaction-related expenses mainly
Madrid, Spain and Heidelberg, Germany, 15 July 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering and the subsequent private placement. Through these transactions, including the contribution in kind, the Company’s share capital will increase by EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 through the issue of 20,538,089 shares by way of a rights offering.
Existing shareholders subscribed a total number of 3,016,734 new shares. Further 1.801.466 shares were placed at a subscription price of EUR 1.10 per share with qualified investors in a subsequent rump placement, which resulted in gross proceeds of EUR 5.3 million. 15.719.889 remaining shares will be offered to Expedeon shareholders against contribution in kind.
Gross proceeds from the cash capital increase will be used for transaction-related expenses, including EUR 1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital.
Pilar de la Huerta, CEO and CFO of SYGNIS AG, said: “We would like to thank all our shareholders for supporting this important transaction and are pleased to announce its completion. The acquisition of Expedeon will transform SYGNIS into a truly international player and will not only improve our strategic position but will allow us to achieve important operational and financial milestones.” Heikki Lankriet, CEO of Expedeon, added: “We are excited to become part of the SYGNIS group and look forward to execute our growth strategy and further exploit the huge potential of innovation at SYGNIS and Expedeon.”
For further information, please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
• Acquisition of Expedeon Holdings Ltd. secured
• Gross proceeds to cover additional cash payments to Expedeon shareholders and transaction-related expenses mainly
Madrid, Spain and Heidelberg, Germany, 15 July 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering and the subsequent private placement. Through these transactions, including the contribution in kind, the Company’s share capital will increase by EUR 20,538,089.00 from EUR 16,803,891.00 to EUR 37,341,980.00 through the issue of 20,538,089 shares by way of a rights offering.
Existing shareholders subscribed a total number of 3,016,734 new shares. Further 1.801.466 shares were placed at a subscription price of EUR 1.10 per share with qualified investors in a subsequent rump placement, which resulted in gross proceeds of EUR 5.3 million. 15.719.889 remaining shares will be offered to Expedeon shareholders against contribution in kind.
Gross proceeds from the cash capital increase will be used for transaction-related expenses, including EUR 1.7 million cash payments to Expedeon shareholders, one-off integration costs and financing working capital.
Pilar de la Huerta, CEO and CFO of SYGNIS AG, said: “We would like to thank all our shareholders for supporting this important transaction and are pleased to announce its completion. The acquisition of Expedeon will transform SYGNIS into a truly international player and will not only improve our strategic position but will allow us to achieve important operational and financial milestones.” Heikki Lankriet, CEO of Expedeon, added: “We are excited to become part of the SYGNIS group and look forward to execute our growth strategy and further exploit the huge potential of innovation at SYGNIS and Expedeon.”
For further information, please contact:
SYGNIS AG
Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS, headquartered in Germany and Spain, specializes in the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast-growing fields of molecular biology and next-generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to a leading industry partner, for whole genome DNA amplification and sequencing, as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed on the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
